Compare Inovio Pharmaceuticals Inc (INO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Uranium Energy Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Uranium Energy Corp trades at $9.19 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 40.4× Inovio Pharmaceuticals Inc's market cap, and Inovio Pharmaceuticals Inc is trading nearer its 52-week high, Uranium Energy Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Uranium Energy Corp for 37 Days on average.
| INO | UEC | |
|---|---|---|
Market Cap | $112.19M | $4.53B |
Volume | 3,201,278 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $2.60 | $20.14 |
52-Week Low | $0.66 | $9.04 |
Typical Hold Time | 43 Days | 37 Days |
Enterprise Value | $83.51M | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.09, down 5.63% today, with a bearish technical outlook and negative financial metrics including a net income margin of -130,000% and ROE of -409.87%. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, though recent earnings have beaten expectations. Key near-term catalyst is the FDA decision on INO-3107 by October 30, 2026.
Despite analyst consensus favoring Buy ratings (58.83%) with a $2.75 price target, INO carries high risk due to persistent cash burn, negative profitability, and dependency on regulatory approvals. The stock offers speculative upside if INO-3107 gains approval but remains vulnerable to further dilution and operational setbacks.
Uranium Energy (UEC) trades at $9.14, down 3.48% today, amid bearish technical signals despite strong analyst support. The company reported fiscal 2026 revenue of $37M but a net loss of $137M, reflecting operational challenges. Recent news highlights production expansion at two U.S. mines and unhedged sales strategy delivering $93.13 per pound realized price. Cash flow remains negative from operations but positive overall due to significant financing activities.
UEC faces fundamental headwinds with negative profitability metrics and high valuation ratios, though Wall Street maintains bullish sentiment with 87.5% buy ratings and $16.06 consensus price target. Key risks include production sustainability questions and dependence on uranium price volatility. The stock offers speculative upside if operational improvements materialize amid growing nuclear energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
